TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01647685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
Study: NCT02819375
Drug: Propofol+Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg propofol+0.5 mg/kg remifentanil
Study: NCT00321412
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, sachet, 2 grams three times daily for 8 weeks
Study: NCT02475447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo-matched control
Study: NCT03910946
Drug: Tuberculin, Purified Protein 5Unt/0.1 mL Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculosis (diagnosis)-Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
Study: NCT00469729
Drug: StemEx®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
Study: NCT02777788
Drug: JinFuKang
Approvals — FDA: no, EMA: no, PMDA: no
Description: treated with chemotherapy
Study: NCT02777788
Drug: XingZaoRuanJian
Approvals — FDA: no, EMA: no, PMDA: no
Description: treated with chemotherapy
Study: NCT02119000
Drug: PEG/electrolytes 2L/2L split dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
Study: NCT00985374
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg or 10mg po daily
Study: NCT00985374
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16mg/kg iv every 3 weeks
Study: NCT03672825
Drug: REcycled CartiLage Auto/Allo IMplantation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
Study: NCT03583346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
Study: NCT00025142
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00025142
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025142
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02716285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, containing microcrystalline cellulose
Study: NCT00074191
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01191385
Drug: Any treatment for unresectable HCC as chosen by the physician
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
Study: NCT01410604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet of 500 mg oral placebo every 12 hours for 3 months.
Study: NCT00406237
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
Study: NCT00753142
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.
Study: NCT02537925
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg bid po, to the end of concurrent radiotherapy
Study: NCT02205138
Drug: ALLOB® cells with ceramic scaffold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
Study: NCT01667614
Drug: spironolacone 25 mg tablets added to losartan
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: spironolactone 25 mg once daily added to losartan
Study: NCT01625182
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT02412319
Drug: Anti-HBV placenta transfer factor injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
Study: NCT00447278
Drug: Other standard therapy for ADHD
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
Study: NCT02024009
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given in combination with gemcitabine, known as GemCap.
Study: NCT01897389
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
Study: NCT01897389
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
Study: NCT04172272
Drug: Systemic multimodal analgesia administered intravenously
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed.
Study: NCT02201576
Drug: Plasma exchanges and intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~3. oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)
Study: NCT02967887
Drug: cisplatin and 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
Study: NCT02022527
Drug: Placebo (for Aspirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic 75 mg Aspirin
Study: NCT00731198
Drug: Hyoscine-N-butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
Study: NCT00420836
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03736369
Drug: DWP14012 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40mg, tablet, orally, once daily for up to 8 weeks
Study: NCT03736369
Drug: DWP14012 40mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
Study: NCT02184117
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
Study: NCT02184117
Drug: Contrast Media
Normalized name: CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of contrast medium to induce hyperemia for contrast FFR
Study: NCT00820092
Drug: Xerecept 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hour infusion
Study: NCT00820092
Drug: Xerecept 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hour infusion
Study: NCT00820092
Drug: Xerecept 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hour infusion
Study: NCT01374789
Drug: GemCis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
Study: NCT05141994
Drug: 2.5mg of BAT5906
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 2.5mg of BAT5906
Study: NCT02447029
Drug: vaginal 2% Xylocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
Study: NCT02568423
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02568423
Drug: Placebo - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00694343
Drug: Ringer's Lactate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mL Ringer's Lactate solution
Study: NCT01257542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 10 mL dose of matching placebo syrup
Study: NCT03177850
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT00875667
Drug: Investigators choice single agent
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
Study: NCT02162433
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: to arms 2,4. Serves as the placebo.
Study: NCT01609192
Drug: Hydrea® (hydroxyurea )
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
Study: NCT01194440
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01684800
Drug: C: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 orally disintegrating tablet every night during study period
Study: NCT01145222
Drug: A. CNS 7056
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial low dose plus supplemental doses as necessary.
Study: NCT01145222
Drug: B. CNS 7056
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial intermediate dose plus supplemental doses as necessary.
Study: NCT01145222
Drug: C. CNS 7056
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial high dose plus supplemental doses as necessary.
Study: NCT01674855
Drug: PEG-G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
Study: NCT00668564
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days before Transplant Drug Frequency~* 4 Cyclophosphamide Once, given over 2 hours~* 3 Cyclophosphamide Once, given over 2 hours~* 2 Cyclophosphamide Once, given over 2 hours~* 1 Cyclophosphamide Once, given over 2 hours
Study: NCT00668564
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours
Study: NCT02911467
Drug: Pyruvate (13C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyruvate injection followed by an MRI scan.
Study: NCT01625520
Drug: SOM230 alone or in combination with RAD001.
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
Study: NCT00368979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03597555
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
Study: NCT00232154
Drug: Zithromax&#153; (azithromycin) 500mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02734147
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01848002
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
Study: NCT03303079
Drug: TEV-48125
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEV-48125 will be subcutaneously administered once monthly for 3 months.
Study: NCT03303079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be subcutaneously administered once monthly for 3 months.
Study: NCT01596660
Drug: Bupivacaina 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaina 0.5% 20cc
Study: NCT01596660
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 cc of saline solution 0.9%, to infiltrate each side.
Study: NCT03476577
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients are tested for their normal prescription ibuprofen medication
Study: NCT01149538
Drug: Choline bitartrate
Normalized name: Choline Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
Study: NCT00106561
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01566825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
Study: NCT03052673
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
Study: NCT00728923
Drug: NPL-2003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (NPL-2003) daily for 12 weeks
Study: NCT01906164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00138476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
Study: NCT01713127
Drug: remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01713127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01804335
Drug: CD5789 0.01% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
Study: NCT00565760
Drug: Q8003
Normalized name: POUCH,DRAINABLE,NEW IMAGE H#18003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT00565760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT03485456
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
Study: NCT00640432
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg oral capsule twice daily for 7 days
Study: NCT00640432
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg oral capsule followed by 200 mg oral capsule with the evening meal (\>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
Study: NCT01765881
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of one sustained released pessary of 10 milligrams by intravaginal route
Study: NCT01663987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day (QD)
Study: NCT02006654
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, matching placebo capsules, orally
Study: NCT00890318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
Study: NCT02506140
Drug: Ticagrelor and Acetylsalicylic acid
Normalized name: codeine and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
Study: NCT02487485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral dose
Study: NCT01122953
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
Study: NCT03135795
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.
Study: NCT03135795
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.
Study: NCT00945620
Drug: ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
Study: NCT00945620
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00849472
Drug: doxorubicin + cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
Study: NCT01761227
Drug: Fufangdanshen Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
Study: NCT01761227
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 tablets per time, 3 times per day for 24 weeks
Study: NCT02506140
Drug: Clopidogrel and Acetylsalicylic acid
Normalized name: codeine and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
Study: NCT00309244
Drug: Technosphere® Insulin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation, 15U/30U
Study: NCT00902967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets of similar shape size and color given once a day at night time after meals
Study: NCT03601052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection at site of second excisional wound
Study: NCT01227395
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults.
Study: NCT01990781
Drug: N: Normal saline (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline: 2ml
Study: NCT00286455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
Study: NCT01501513
Drug: PEG-3350 based bowel preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for oral administration prior to colonoscopy
Study: NCT01501513
Drug: BLI800 approved preparation regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for oral administration prior to colonoscopy
Study: NCT01501513
Drug: BLI800 investigational preparation regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for oral administration prior to colonoscopy
Study: NCT03698916
Drug: Celecoxib cream 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal delivery of 8% Celecoxib
Study: NCT00890162
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00890162
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01312129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule x 3 doses 12 hours apart
Study: NCT03720847
Drug: Estradiol Transdermal Patch 0.1 mg/24 hrs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
Study: NCT03720847
Drug: Inactive Clear Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
Study: NCT03720847
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Study: NCT04257617
Drug: ZL-1201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.